Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer

Ya Chen Tina Shih; Linda S. Elting; Alexandre L. Pavluck; Andrew Stewart; Michael T. Halpern

doi:10.3109/07357900902783187

Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer

Ya Chen Tina Shih, Linda S. Elting, Alexandre L. Pavluck, Andrew Stewart, Michael T. Halpern

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

We analyzed the utilization trend for immunotherapy as initial treatment in the United States and estimated the cost impact of three cancers for which the majority of newly approved immunotherapies were indicated: non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), and metastatic colorectal cancer (MCRC). Utilization was highly concentrated, with four cancers accounting for 7080 of use. On the basis of the pattern in 2004 (22.9 NHL, 3.2 MCRC, and 3.3 MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50 of eligible patients received immunotherapy.

Original language	English (US)
Pages (from-to)	46-53
Number of pages	8
Journal	Cancer Investigation
Volume	28
Issue number	1
DOIs	https://doi.org/10.3109/07357900902783187
State	Published - 2010
Externally published	Yes

Keywords

Health sciences research
Monoclonal antibodies
Outcomes research

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3109/07357900902783187

Cite this

@article{ca18a968564941d38fcb1a8e757ba012,

title = "Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer",

abstract = "We analyzed the utilization trend for immunotherapy as initial treatment in the United States and estimated the cost impact of three cancers for which the majority of newly approved immunotherapies were indicated: non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), and metastatic colorectal cancer (MCRC). Utilization was highly concentrated, with four cancers accounting for 7080 of use. On the basis of the pattern in 2004 (22.9 NHL, 3.2 MCRC, and 3.3 MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50 of eligible patients received immunotherapy.",

keywords = "Health sciences research, Monoclonal antibodies, Outcomes research",

author = "Shih, {Ya Chen Tina} and Elting, {Linda S.} and Pavluck, {Alexandre L.} and Andrew Stewart and Halpern, {Michael T.}",

year = "2010",

doi = "10.3109/07357900902783187",

language = "English (US)",

volume = "28",

pages = "46--53",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Immunotherapy in the initial treatment of newly diagnosed cancer patients

T2 - Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer

AU - Shih, Ya Chen Tina

AU - Elting, Linda S.

AU - Pavluck, Alexandre L.

AU - Stewart, Andrew

AU - Halpern, Michael T.

PY - 2010

Y1 - 2010

N2 - We analyzed the utilization trend for immunotherapy as initial treatment in the United States and estimated the cost impact of three cancers for which the majority of newly approved immunotherapies were indicated: non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), and metastatic colorectal cancer (MCRC). Utilization was highly concentrated, with four cancers accounting for 7080 of use. On the basis of the pattern in 2004 (22.9 NHL, 3.2 MCRC, and 3.3 MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50 of eligible patients received immunotherapy.

AB - We analyzed the utilization trend for immunotherapy as initial treatment in the United States and estimated the cost impact of three cancers for which the majority of newly approved immunotherapies were indicated: non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), and metastatic colorectal cancer (MCRC). Utilization was highly concentrated, with four cancers accounting for 7080 of use. On the basis of the pattern in 2004 (22.9 NHL, 3.2 MCRC, and 3.3 MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50 of eligible patients received immunotherapy.

KW - Health sciences research

KW - Monoclonal antibodies

KW - Outcomes research

UR - http://www.scopus.com/inward/record.url?scp=72449132792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449132792&partnerID=8YFLogxK

U2 - 10.3109/07357900902783187

DO - 10.3109/07357900902783187

M3 - Article

C2 - 19995227

AN - SCOPUS:72449132792

SN - 0735-7907

VL - 28

SP - 46

EP - 53

JO - Cancer Investigation

JF - Cancer Investigation

IS - 1

ER -

Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this